CN213697466U - Ophthalmic surface drug delivery device - Google Patents

Abstract

The utility model provides an eye table medicine conveyor, it includes hollow first arm and the second arm that combines with first arm, wherein, first arm one end has the interface to towards the first arm other end, first arm is equipped with the dosing hole in the outside, and the dosing hole communicates with the well kenozooecium fluid of interface via first arm. The utility model discloses an ocular surface drug delivery device does not need the patient to keep specific position, does not require patient's head/eye to keep at any horizontal position promptly, still can carry whole ocular surface with the medicine in succession simultaneously to/or can avoid taking place mechanical friction's risk between device and the ocular surface.

Description

Ophthalmic surface drug delivery device

Technical Field

The utility model relates to a medical apparatus, in particular to an ophthalmic clinical treatment appliance, in particular to an ocular surface drug delivery device.

Background

In ophthalmic clinics, infectious keratoscleritis such as persistent is very common. Even with current anti-pathogen drug treatments, there is a need for treatment with increased drug concentrations and increased dosing times. To facilitate treatment of such recalcitrant infections, the inventors previously developed an ocular surface irrigator that achieved the goal of eradicating the infection in many clinical cases. See the inventor's et al papers "Treatment of Pseudomonas keypoints by coherent sources in fusion of topical anti-inflammatory drugs of high molecular lens a needle series report" (Cornea, 5.2017, 36 (5: 617-) -620) and "synthetic on ocular pharmacologics of systemic infiltration of heterologous proteins beta coherent sources and systemic induction in mutations" (Cornea, 11.2018, 37(11):1457-

An example of an eye surface irrigator is described in the applicant's own chinese utility model patent No. cn206434569u, which comprises a cover body for placing in the conjunctival sac and fitting with the eye surface, a drainage port connected to the outer side of the cover body and communicating with the inner side of the cover body, and a drainage hose connected to the drainage port.

However, the existing ocular surface irrigators have the following disadvantages. First, to ensure that the drug covers the entire ocular surface, delivery of the drug to the ocular surface by means of a continuous lavage via an ocular surface irrigator requires that the patient receiving the treatment be in a horizontal position (lying down). If the patient adopts a sitting or semi-sitting position during the treatment, the drug can only be delivered to the lower ocular surface area due to gravity, and the infected area above the horizontal midline cannot be sufficiently covered by the drug, thus failing to achieve the purpose of effective treatment. Second, the treatment with such a continuous irrigation may last several days, and it would be very difficult to require the patient to keep the head/eye in a horizontal position at all times. Third, existing ocular surface irrigators are shaped as inverted funnels that are typically placed over the corneosclera, in many cases leaving an arch space over the cornea, allowing a fluid space between the inner surface of the irrigator and the ocular surface. However, due to the different ocular surface anatomy and even corneal curvature of different people, there may be a risk of mechanical friction occurring between the inner surface of the ocular surface irrigator and the ocular surface, resulting in additional pain in addition to the pain and irritation caused by the infection itself. Furthermore, mechanical abrasion can also damage the affected surface of the cornea being healed.

Disclosure of Invention

In view of the above, it is an object of the present invention to provide an ophthalmic drug delivery device that overcomes at least one of the above-mentioned disadvantages. To this end, the inventors have developed an improved ocular surface drug delivery device which does not require the patient to maintain a particular position, i.e. does not require the patient's head/eye to remain in any horizontal position, while still being able to deliver drug continuously to the entire ocular surface and/or being able to avoid the risk of mechanical friction between the device and the ocular surface.

According to the utility model discloses, provide an eye table medicine conveyor, it includes hollow first arm and the second arm that combines with first arm, wherein, first arm one end has the interface to towards the first arm other end, first arm is equipped with the dosing hole in the outside, and the dosing hole is with the well kenozooecium fluid intercommunication of interface via first arm.

According to an embodiment, a plurality of dosing holes are provided, distributed along the extension direction of the first arm, for example, in a direction towards the other end of the first arm, with three dosing holes, a middle and a far dosing hole or two dosing holes, the distal dosing hole being located at or close to the other end of the first arm. Preferably, the administration aperture opens towards the second arm.

According to an embodiment, the second arm may also be hollow, communicating with the first arm at the junction and towards the end of the second arm remote from the first arm interface, the second arm being provided with the administration aperture on the outside, thereby placing the administration aperture in fluid communication with the interface. Preferably, the administration aperture of the second arm opens towards the first arm.

Preferably, the first arm is an upper arm and the second arm is a lower arm. It is also possible that the first arm is a lower arm and the second arm is an upper arm.

Preferably, an administration aperture is provided at the other end of the upper arm such that, in use, the administration aperture is adjacent the opening of the major lacrimal gland in the upper orbit.

According to an embodiment, the upper arm and the lower arm each comprise: an intersection portion intersecting at the joint portion, and a parallel portion extending from a tip of the intersection portion away from the joint portion and substantially parallel to each other, thereby forming a square-fork-like configuration. Preferably, the square-forked configuration substantially follows the contour of the vault region of the human eye.

According to an embodiment, the upper arm is made of a metal tube, such as copper, stainless steel, titanium alloy or other eye surface usable metals. The metal tube is, for example, a 15 to 19 gauge tube or a similar gauge tube. Alternatively, the device may be made of a flexible synthetic medical material, including but not limited to silicone, plastic or fabric, or other suitable medical material.

According to an embodiment, the lower arm is solid, e.g. made of an elastic solid wire, similar in thickness to the upper arm. It is also possible that the lower arm is also hollow tubular, the outer side of the parallel portion of which is provided with an administration aperture preferably opening towards the parallel portion of the upper arm, and that the lower arm communicates with the upper arm at a junction, thereby bringing the administration aperture of the lower arm into fluid communication with the upper arm interface.

According to an embodiment, the ocular surface drug delivery device further comprises a connector connected to the interface. The connector is a medical needle tail part (such as a luer connector) with a conventional specification and is used for connecting with a conventional intravenous infusion tube.

According to an embodiment, the upper arm and the lower arm are joined in one piece, the lower arm being an extension of the end of the upper arm.

According to other embodiments, the ocular surface drug delivery device may be in a semi-annular, open ring, or closed ring configuration, among others. In the semi-annular configuration, the second arm is joined to the first arm only at its end adjacent the interface end of the first arm. In the closed loop configuration, the second arm is joined to the first arm at both ends. In the open loop configuration, the second arm is joined to the first arm only at the end thereof distal from the first arm interface end.

According to a specific embodiment, the first arm includes a linear portion extending from the interface end and a curved portion interfacing with the linear portion, and the second arm is curved with one end joined to the first arm at the interface and the other end joined to the other end of the first arm, thereby forming a closed loop configuration.

According to another embodiment, the first arm includes a linear portion extending from the interface end and a curved portion interfacing with the linear portion, and the second arm is curved with one end joined to the first arm at the interface and the other end not joined to the first arm, thereby forming an open loop configuration.

According to another embodiment, the first arm includes a linear portion extending from the interface end and a curved portion interfacing with the linear portion, and the second arm is curved, joined to the first arm at one end distal from the interface, and joined to the first arm at the other end, thereby forming a semi-annular configuration.

In clinical use, the ocular surface drug delivery device is placed under the upper and lower eyelids (sub-eyelids), i.e., in the upper and lower fornix regions of the conjunctiva, with the upper arm in the upper fornix region and the lower arm in the lower fornix region, i.e., contained at the inflection point of the bulbar conjunctiva and palpebral conjunctiva. Thus, even in the absence of gravitational forces, the drug delivered to this location will diffuse across the ocular surface following the natural physiological distribution path of tears under the closed eyelids. In addition, when the patient takes the standing position, the liquid medicine naturally flows downward due to the gravity.

After connecting the bag (bottle) of liquid medicine with the delivery device via the connector in a manner similar to intravenous infusion, infusion of the liquid medicine can be started at a controlled rate, and the liquid medicine will be delivered to the spaces of the conjunctival superior fornix. With the progressive closure of the upper and lower eyelids upon blinking, the delivered drug will spread evenly over the ocular surface (the inner surface of the eyelid), naturally covering the entire ocular surface, regardless of the position of the head/eye. Thus, the patient can adopt the body positions of lying, sitting upright, sitting semi-sitting and the like, and even can walk at any time without influencing the administration.

Furthermore, the utility model discloses an ocular surface drug delivery device does not take place the contact with the cornea surface, has avoided taking place mechanical friction's risk. In addition, the patient can freely open and close the treated eye during treatment, facilitating immediate clinical evaluation during treatment, and even the doctor can monitor the condition of ocular surface tissue change and vision of the patient without taking out the device.

Besides being used for drug administration, the ocular surface drug delivery device of the utility model can also be used for the washing of the ocular surface, such as the treatment of chemical or thermal burns, the accidental entry of foreign particles into the eyes and the like, and can also be used for the thorough disinfection of the ocular surface before and after operations or during trauma.

Drawings

The features and advantages of the present invention will be apparent from the following detailed description of embodiments thereof, which proceeds with reference to the accompanying drawings. In the drawings:

fig. 1 is a schematic view of an ocular surface drug delivery device according to a first embodiment of the present invention;

fig. 2 is a schematic view of the ocular surface drug delivery device of fig. 1 in use (i.e., placed in the eye);

fig. 3 is a schematic view of an ocular surface drug delivery device according to a second embodiment of the present invention;

fig. 4 is a schematic view of an ocular surface drug delivery device according to a third embodiment of the present invention;

fig. 5 is a schematic view of an ocular surface drug delivery device according to a fourth embodiment of the present invention;

the drawings are not necessarily to scale. Like reference symbols in the various drawings indicate like elements.

List of reference numerals

1. 100, 200, 300 ocular surface drug delivery device

10. 110, 210, 310 Upper arm

11. 21 intersection part

12. 22 parallel portion

20. 120, 220, 320 lower arm

30. 130, 230, 330 administration hole

40. 140, 240, 340 joint

50. 150, 250 proximal junction

160. 360 distal junction

111. 211, 311 linear part

112. 212, 312 curved part

A Upper eyelid

Lower eyelid

Temporal side C

D nasal side

Detailed Description

An ocular surface drug delivery device according to an embodiment of the present invention is described in detail below with reference to the accompanying drawings. For ease of description, directional terminology is used in the description, wherein "up", "down", etc. refer to directions in the drawings, and "distal" and "proximal" refer to directions away from and toward the joint, respectively.

Referring to fig. 1, the ophthalmic drug delivery device 1 comprises a hollow tubular upper arm 10 and a flexible lower arm 20 combined with the upper arm, wherein one end (proximal end) of the upper arm is a mouthpiece end, and the upper arm is provided with three proximal, middle and distal administration holes 30 towards the other end (distal end) of the upper arm, the distal administration hole 30 is located at the distal end of the upper arm. The three administration holes 30 are each open towards the lower arm 20 and in fluid communication with the mouthpiece end via the hollow of the upper arm 10.

The upper arm 10 and the lower arm 20 form a square fork-like configuration, each arm comprising: linear intersections 11 and 21, intersections 11 and 21 intersecting at a proximal junction 50; and parallel portions 12 and 22 extending from distal ends of the respective intersecting portions 11 and 21 away from the joint portion 50 and substantially parallel to each other. In this example, the mouthpiece end is located at the intersection 11 of the upper arm 10, the proximal junction 50 is located at the middle of the intersection 11 of the upper arm 10, and the three administration holes 30 are evenly distributed along the parallel portion 12 of the upper arm 10.

Additionally, the hub end is welded with a luer fitting 40 for connection to an intravenous line for delivering medication to the ocular surface via administration port 30.

Fig. 2 shows a schematic view of the ocular surface drug delivery device 1 of fig. 1 in clinical use, i.e. placed in the eye. In clinical use, as shown in fig. 2, the ocular surface drug delivery device 1 is placed under the upper and lower eyelids (under the upper eyelid a and the lower eyelid B), i.e., the upper and lower fornix regions of the conjunctiva, the upper arm 10 is located in the upper fornix region (not shown), the lower arm 20 is located in the lower fornix region (not shown), and the distal administration hole 30 is located near the opening of the major lacrimal gland located in the upper orbit

In fig. 2, the interface end of the upper arm is close to the temporal side C, and the other end is close to the nasal side D. Thus, the ocular surface drug delivery device shown in fig. 2 is suitable for use in the left eye. For the right eye, a mirror symmetric configuration of the ocular surface drug delivery device shown in fig. 2 may be used.

In addition to the square fork like configuration of fig. 1, the ocular surface drug delivery device may have other configurations such as a semi-annular, open ring or closed ring, etc. Fig. 3 shows a second embodiment of an ocular surface drug delivery device 100 comprising a hollow tubular upper arm 110 in combination with a likewise hollow tubular lower arm 120. The upper arm proximal end is a mouthpiece end, and includes a linear portion 111 extending from the mouthpiece end and a curved portion 112 joining the linear portion 111 at a proximal end joining portion 150, and toward the upper arm distal end, the curved portion 112 is provided with three proximal, middle, and distal administration holes 130 on the outside. The three administration holes 130 are each open toward the lower arm 120 and in fluid communication with the mouthpiece end via the hollow portion of the upper arm 10. The lower arm 120 is also provided with three proximal, middle and distal administration holes 130 on the outside, and all of the three administration holes 130 open toward the upper arm 110. In this example, the lower arm 120 is curved, joined at a proximal end to the upper arm 110, and also joined at a distal end to the upper arm 110, whereby the upper arm 110 and the lower arm 120 form a closed loop configuration. Upper arm 110 and lower arm 120 communicate at proximal junction 150 and/or distal junction 160 such that administration port 130 and the mouthpiece end of lower arm 120 are in fluid communication via the hollow of lower arm 120. Additionally, the mouthpiece end is welded with a luer fitting 140 for connection to an intravenous line for delivering medication to the ocular surface via administration port 130.

Fig. 4 shows a third embodiment of an ophthalmic drug delivery device 200 comprising a hollow tubular upper arm 210 and a likewise hollow tubular lower arm 220 joined thereto, the upper arm proximal end being a mouthpiece end and comprising a linear portion 211 extending from the mouthpiece end and a curved portion 212 meeting the linear portion 211 at a junction 250, and the lower arm being curved. In this example, upper arm 210 and lower arm 220 are similar to the second embodiment except that lower arm 220 is joined to upper arm 210 only at the proximal end and is not joined to upper arm 210 at the distal end, whereby upper arm 210 and lower arm 220 form a semi-annular configuration and dosing holes 230 at the distal side of upper arm 210 and lower arm 220 are located just at the distal end of the respective arms. Upper arm 210 communicates with lower arm 220 at junction 250 such that administration port 230 and the mouthpiece end of lower arm 220 are in fluid communication via the hollow of lower arm 220. In addition, luer 240 is welded to the mouthpiece end for connection to an intravenous line for delivering medication to the ocular surface via administration port 230.

Fig. 5 shows a fourth embodiment of an ophthalmic drug delivery device 300 comprising a hollow tubular upper arm 310 and in combination therewith a likewise hollow tubular lower arm 320, the proximal end of the upper arm being a mouthpiece end and comprising a linear portion 311 extending from the mouthpiece end and a curved portion 312 interfacing the linear portion 311, and the lower arm being curved. In this example, the upper arm 310 and the lower arm 320 are similar to the second and third embodiments, except that the lower arm 320 is joined to the upper arm 310 only at the distal end, but not joined to the upper arm 310 at the proximal end, whereby the upper arm 310 and the lower arm 320 form an open loop configuration, and the administration hole 330 at the proximal side of the lower arm 320 is located just at the proximal end of the lower arm 320. The upper arm 310 communicates with the lower arm 320 at a distal junction 360 such that the administration port 330 of the lower arm 320 is in fluid communication with the mouthpiece end via the hollow of the lower arm 320. In addition, the mouthpiece end is welded with a luer fitting 340 for connection to an intravenous line for delivering medication to the ocular surface via the administration port 330.

In clinical use, the upper and lower arms of the ocular surface drug delivery device may be slightly curved to better conform to the contours of the vault area of the human eye, as the case may be, and the junction of the linear and curved portions (see fig. 3-5) or the junction at the junction may also be appropriately curved to accommodate insertion into the vault area from the external corner of the eye.

The embodiments described herein are merely illustrative. In some cases, features disclosed in the present disclosure may be used independently of other features. On the other hand, when necessary, the features disclosed in the present invention may be combined to provide various combinations. Accordingly, the present invention is not limited to the embodiments shown herein. Based on the embodiments of the present invention, those skilled in the art can obtain other embodiments without creative efforts, and these embodiments all belong to the protection scope of the present invention. Thus, the present invention is to be accorded the widest scope consistent with the principles disclosed herein.

Claims (13)

1. An ocular surface drug delivery device comprising a hollow first arm and a second arm joined to the first arm, wherein the first arm has a mouthpiece at one end and is provided with an administration hole on the outside toward the other end of the first arm, the administration hole and the mouthpiece being in fluid communication via a hollow portion of the first arm.

2. The ocular surface drug delivery device of claim 1, wherein there are three or two of the proximal, middle and distal drug delivery apertures in a direction towards the other end of the first arm.

3. The ocular surface drug delivery device of claim 1, wherein the administration aperture opens toward the second arm.

4. The ocular surface drug delivery device of claim 1, wherein an administration aperture is provided at the other end of the first arm.

5. The ocular surface drug delivery device of claim 1, wherein the second arm is hollow, communicates with the first arm at a junction, and is directed towards an end of the second arm distal from the first arm port, the second arm being provided with the administration port on an outer side, thereby placing the administration port of the second arm in fluid communication with the port.

6. The ocular surface drug delivery device of claim 5, wherein the administration aperture of the second arm opens toward the first arm.

7. The ocular surface drug delivery device of any one of claims 1-6, wherein the first and second arms each comprise an intersection that intersects at a junction, parallel portions that extend from ends of the intersections away from the junction and parallel to each other, thereby forming a square-forked configuration.

8. The ocular surface drug delivery device of claim 7, wherein the harpoon-like configuration follows the contours of the vault region of the human eye.

9. The ocular surface drug delivery device of any one of claims 1 to 6, wherein the second arm is joined to the first arm at its end adjacent the interface end of the first arm, and the other end is not joined to the first arm, such that a semi-annular configuration is formed.

10. The ocular surface drug delivery device of any of claims 1-6, wherein the second arm is joined to the first arm at both ends such that a closed loop configuration is formed.

11. The ocular surface drug delivery device of any one of claims 1-6, wherein the second arm is joined to the first arm at its end distal to the interface end of the first arm, and the other end is not joined to the first arm, such that an open loop configuration is formed.

12. An ocular surface drug delivery device according to any of claims 1-6, wherein the first arm and the second arm are integral, the second arm being an extension of an end of the first arm.

13. The ocular surface drug delivery device of any of claims 1-6, further comprising a connector connected to the interface.

Images